Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Dermatology
•
Systemic autoimmune diseases
Do you see a role for early, aggressive treatment for MCTD to prevent progression of disease, even though there has not been end-organ manifestations?
Related Questions
What considerations do you take when using prednisone in patients with systemic sclerosis?
How do you go about switching from one DMARD to another In patients with dermatomyositis that remains active?
How do you optimize retinopathy screening schedules for patients on hydroxychloroquine while also prioritizing cost-effectiveness?
What treatments have you found most effective for cholestatic pruritus?
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
How do you approach managing nausea and GI side effects when initiating methotrexate?
How would you approach management of an elderly patient with known mantle cell lymphoma and new diagnosis of cryoglobulinemic vasculitis with mild skin involvement, fatigue, arthralgias but no other major organ involvement?
How do you treat IgA cutaneous vasculitis with retiform purpura and evidence of fibrinoid necrosis on skin biopsy?
How would you approach management of a patient who develops squamous cell skin cancer while on abatacept?
How do you approach management of patients with psoriatic arthritis who have significant improvement in skin disease, but ongoing inflammatory arthritis despite multiple DMARDs and/or biologics?
